In last trading session, Nuvation Bio Inc (NYSE:NUVB) saw 5.55 million shares changing hands with its beta currently measuring 1.30. Company’s recent per share price level of $2.24 trading at -$0.05 or -2.18% at ring of the bell on the day assigns it a market valuation of $758.64M. That closing price of NUVB’s stock is at a discount of -85.71% from its 52-week high price of $4.16 and is indicating a premium of 25.45% from its 52-week low price of $1.67. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.73 million shares which gives us an average trading volume of 2.55 million if we extend that period to 3-months.
For Nuvation Bio Inc (NUVB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.
Nuvation Bio Inc (NYSE:NUVB) trade information
Upright in the red during last session for losing -2.18%, in the last five days NUVB remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $2.24 price level, adding 7.44% to its value on the day. Nuvation Bio Inc’s shares saw a change of -15.79% in year-to-date performance and have moved 19.79% in past 5-day. Nuvation Bio Inc (NYSE:NUVB) showed a performance of -1.75% in past 30-days. Number of shares sold short was 24.66 million shares which calculate 14.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 68.0% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -212.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -212.5% for stock’s current value.
Nuvation Bio Inc (NUVB) estimates and forecasts
This year revenue growth is estimated to rise 72.24% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 416.67k for the same. And 6 analysts are in estimates of company making revenue of 416.67k in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -49.14% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 73.12% while estimates for its earnings growth in next 5 years are of 37.20%.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Insiders are in possession of 26.68% of company’s total shares while institution are holding 59.37 percent of that, with stock having share float percentage of 80.97%. Investors also watch the number of corporate investors in a company very closely, which is 59.37% institutions for Nuvation Bio Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at NUVB for having 28.82 million shares of worth $84.16 million. And as of 2024-06-30, it was holding 13.1578 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 19.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8491 of outstanding shares, having a total worth of $56.09 million.
